Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for mTOR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | mTOR Kinase Domain & Full-Length Mutant Protein (Wild-type + L1460P, A1459P mutants). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. HEK293 Expressed. | View MTOR Products |
| Gene Delivery | mTOR Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. HEK293 packaged, high titer (>10^8 TU/mL). | View MTOR Products |
| Benchmark Ab | Anti-mTOR / Anti-Phospho-mTOR Antibody (Rabbit mAb Clone). Recombinant positive control for Western Blot, IF, IP, and cellular assay validation. | View MTOR Products |
| Validator | mTOR siRNA Set (3 unique targets). For knockdown verification and target-engagement specificity controls. | View MTOR Products |
| Related Target A | PIK3CA – Upstream PI3Kα kinase; essential for pathway synergy assays and combination therapy counter-screening. | View PIK3CA Products |
| Related Target B | RPTOR – mTORC1-specific scaffolding partner; critical for complex-selective inhibitor development. | View RPTOR Products |
| Related Target C | FKBP1A (FKBP12) – Intracellular co-factor for rapamycin-based allosteric inhibition and bi-steric inhibitor evaluation. | View FKBP1A Products |
| Related Target D | AKT1 – Downstream effector kinase; for pathway validation and resistance studies (mTORC2 readout). | View AKT1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Drug Resistance Mutation Screening (L1460P, A1459P, I2017T, and clinical mutations from lung large cell carcinoma, melanoma, FCORD2) | Sequence-verified mutant mTOR proteins (FAT and kinase domains) with IC50 shift ready; custom panel available. |
| PIKK Family Selectivity (vs PI3Kα/β/γ/δ, DNA-PK, ATM, ATR) | Highly pure mTOR kinase domain (>95%) for biochemical counter-screens; homolog panel verified by mass spec. |
| mTORC1 vs mTORC2 Complex Biochemistry | RPTOR and RICTOR co-expression lentivirus systems for complex assembly and selective inhibition profiling. |
| PROTAC Ternary Complex Validation | Precisely tagged mTOR and E3 ligase (CRBN, VHL) components for reliable SPR and TR-FRET assays. |
| Cell Permeability / CNS Penetration | Stable cell line generation via high-titer mTOR lentivirus; MDCK or hCMEC/D3 models for blood-brain barrier assessment. |
| False Positives / Off-Target Inhibition | Validated siRNA and clinical benchmark antibodies included for specificity checks in cellular pathway assays. |
Live mTOR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for mTOR therapeutics is intensifying, with major players shifting focus from first-generation allosteric rapalogs (sirolimus, everolimus, temsirolimus) to second-generation ATP-competitive dual mTORC1/2 inhibitors (e.g., sapanisertib, vistusertib) and third-generation modalities including bi-steric inhibitors, PROTAC degraders, and CNS-penetrant scaffolds. Key players include Novartis, Pfizer, Takeda, Bayer, AstraZeneca, Revolution Medicines, Arvinas, and academic innovators (Dana-Farber, Gray Lab). Resistance mechanisms in the FAT domain and PI3K/PI4K catalytic domain (mutations such as rs748801456 in lung large cell carcinoma, rs913197212 in familial cortical dysplasia, and acquired L1460P/A1459P) are driving demand for mutant-selective tools. The future outlook emphasizes: (1) expansion of CNS indications (tuberous sclerosis, glioblastoma), (2) PROTAC-mediated degradation to overcome adaptive resistance, (3) mTORC2-selective inhibition for reduced metabolic toxicity, and (4) combination regimens with PI3K inhibitors, CDK4/6 inhibitors, and immune checkpoint blockers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Allosteric Inhibitor (Rapalog) | Novartis, Pfizer | Renal cell carcinoma, breast cancer, TSC, neuroendocrine tumors | Kinase Activity Assay (Need high-purity, sequence-verified mTOR kinase domain + FKBP12 proteins) |
| ATP-Competitive Inhibitor | Novartis, Takeda, AstraZeneca, Bayer | Solid tumors, breast cancer, hematologic malignancies | Resistance Mutation Panel (Need L1460P, A1459P, I2017T mutants for IC50 shift) |
| Bi-steric Inhibitor | Revolution Medicines, Relay Therapeutics | Refractory solid tumors | Affinity/Kinetics (Need full-length/multi-domain active proteins and FKBP12) |
| PROTAC / Degrader | Arvinas, Dana-Farber/Gray Lab, Cullgen | Resistant solid tumors, advanced carcinomas | Ternary Complex Validation (Need pure mTOR and E3 ligase components for SPR/TR-FRET) |
| CNS-Penetrant Inhibitor | Novartis, Academic Labs | TSC, epilepsy, glioblastoma | Cell-Based Permeability (Need stable mTOR-expressing lines for blood-brain barrier models) |
| Combination Therapy (PI3K + mTOR) | Novartis, Genentech, Bayer | PIK3CA-mutant breast cancer, hematologic malignancies | Selectivity Panel (Need PIK3CA + mTOR homolog proteins for cross-reactivity screening) |
Note: All recombinant proteins are sequence-verified and functionally validated for biochemical and cellular assays.